FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108080169> ?p ?o ?g. }

• W2108080169 endingPage "iv156" @default.
• W2108080169 startingPage "iv156" @default.
• W2108080169 abstract "ABSTRACT Aim: Gemcitabine, a nucleoside analogue, and eribulin (E7389), an investigational tubulin-based anti-mitotic drug exhibited synergistic cytotoxic effects pre-clinically and were combined in a Phase I dose finding clinical trial. Methods: A phase I clinical dose-escalation study of these 2 drugs in combination was initiated in patients with advanced solid tumours who had received up to two prior chemotherapy regimens for metastatic disease (CP cohort). Dose escalation was performed in a 3 + 3 design to identify the recommended phase II dose (RPTD). Two additional expansion cohorts consisting of women with gynecologic cancers at the recommended phase II dose (G cohort), and further dose-escalation of chemotherapy-naive patients (CN cohort), were evaluated. Results: Forty five patients were treated in 3 cohorts - 21 (CP), 10 (G), and 14 (CN). The initial combination of eribulin and gemcitabine was administered on days 1, 8, 15 of a 28 day cycle (CP) but due to 2/6 DLTs, a less dose-intense schedule with the 2 drugs given days 1 and 8 on a q21day cycle was assessed. Dose Dose Level N Schedule E7389 (mg/m2) Gemcitbaine (mg/m2) DLT Toxicity 1 (q28) 6 D1,8,15 q28d 0.7 800 2 Thrombocytopenia 1 (q21) 3 D1,8 q21d 0.7 800 2 3 D1,8 q21d 0.7 1000 3-CP 6 D1,8 q21d 1.0 1000 1 Neutropenia 3-G 10 D1,8 q21d 1.0 1000 4-CP 3 D1.8 q21d 1.4 1000 2 Diarrhea; fatigue 4-CN 7 D1,8 q21d 1.4 1000 1 Elevated transaminases 5-CN 5 D1,8 21d 1.6 1000 6-CN 2 D1,8q21d 1.8 1000 1 Neutropenia The RPTD was at dose level 3. No other significant hematologic or non-hematologic toxicities were observed with the CP patients. For the CN cohort, additional escalation at dose levels 4, 5, and 6 was attempted, but due to dose limiting neutropenia seen after Cycle 1, DL3 remained RPTD. Objective responses were seen in all three cohorts – 2/21 (CP), 1/10 (G) and 2/14 (CN). Conclusions: The combination of eribulin and gemcitabine was well tolerated with preliminary evidence of activity being seen. Phase II investigation of this regimen should be considered at a dose of 1.0mg/m2 eribulin and 1000 mg/m2 gemcitabine day 1 and 8 q3 weeks. Support by contract HHSN261201100032C/NO1-CM-2011-00032. Disclosure: All authors have declared no conflicts of interest." @default.
• W2108080169 created "2016-06-24" @default.
• W2108080169 creator A5000832151 @default.
• W2108080169 creator A5007115083 @default.
• W2108080169 creator A5011411233 @default.
• W2108080169 creator A5012785119 @default.
• W2108080169 creator A5033113064 @default.
• W2108080169 creator A5041531063 @default.
• W2108080169 creator A5045742731 @default.
• W2108080169 creator A5058081816 @default.
• W2108080169 creator A5070279783 @default.
• W2108080169 creator A5072712459 @default.
• W2108080169 creator A5077884585 @default.
• W2108080169 creator A5080894374 @default.
• W2108080169 date "2014-09-01" @default.
• W2108080169 modified "2023-09-26" @default.
• W2108080169 title "A Phase I Study of Eribulin and Gemcitabine in Patients with Avanced Solid Tumours. a Study of the Princess Margaret Phase Ii Consortium" @default.
• W2108080169 doi "https://doi.org/10.1093/annonc/mdu331.30" @default.
• W2108080169 hasPublicationYear "2014" @default.
• W2108080169 type Work @default.
• W2108080169 sameAs 2108080169 @default.
• W2108080169 citedByCount "1" @default.
• W2108080169 countsByYear W21080801692019 @default.
• W2108080169 crossrefType "journal-article" @default.
• W2108080169 hasAuthorship W2108080169A5000832151 @default.
• W2108080169 hasAuthorship W2108080169A5007115083 @default.
• W2108080169 hasAuthorship W2108080169A5011411233 @default.
• W2108080169 hasAuthorship W2108080169A5012785119 @default.
• W2108080169 hasAuthorship W2108080169A5033113064 @default.
• W2108080169 hasAuthorship W2108080169A5041531063 @default.
• W2108080169 hasAuthorship W2108080169A5045742731 @default.
• W2108080169 hasAuthorship W2108080169A5058081816 @default.
• W2108080169 hasAuthorship W2108080169A5070279783 @default.
• W2108080169 hasAuthorship W2108080169A5072712459 @default.
• W2108080169 hasAuthorship W2108080169A5077884585 @default.
• W2108080169 hasAuthorship W2108080169A5080894374 @default.
• W2108080169 hasConcept C121608353 @default.
• W2108080169 hasConcept C126322002 @default.
• W2108080169 hasConcept C143998085 @default.
• W2108080169 hasConcept C178790620 @default.
• W2108080169 hasConcept C185592680 @default.
• W2108080169 hasConcept C2775930923 @default.
• W2108080169 hasConcept C2776387010 @default.
• W2108080169 hasConcept C2776694085 @default.
• W2108080169 hasConcept C2780258809 @default.
• W2108080169 hasConcept C31760486 @default.
• W2108080169 hasConcept C44280652 @default.
• W2108080169 hasConcept C530470458 @default.
• W2108080169 hasConcept C71924100 @default.
• W2108080169 hasConceptScore W2108080169C121608353 @default.
• W2108080169 hasConceptScore W2108080169C126322002 @default.
• W2108080169 hasConceptScore W2108080169C143998085 @default.
• W2108080169 hasConceptScore W2108080169C178790620 @default.
• W2108080169 hasConceptScore W2108080169C185592680 @default.
• W2108080169 hasConceptScore W2108080169C2775930923 @default.
• W2108080169 hasConceptScore W2108080169C2776387010 @default.
• W2108080169 hasConceptScore W2108080169C2776694085 @default.
• W2108080169 hasConceptScore W2108080169C2780258809 @default.
• W2108080169 hasConceptScore W2108080169C31760486 @default.
• W2108080169 hasConceptScore W2108080169C44280652 @default.
• W2108080169 hasConceptScore W2108080169C530470458 @default.
• W2108080169 hasConceptScore W2108080169C71924100 @default.
• W2108080169 hasLocation W21080801691 @default.
• W2108080169 hasOpenAccess W2108080169 @default.
• W2108080169 hasPrimaryLocation W21080801691 @default.
• W2108080169 hasRelatedWork W2019621848 @default.
• W2108080169 hasRelatedWork W2066557153 @default.
• W2108080169 hasRelatedWork W2072202432 @default.
• W2108080169 hasRelatedWork W2127804865 @default.
• W2108080169 hasRelatedWork W2338766826 @default.
• W2108080169 hasRelatedWork W2592064345 @default.
• W2108080169 hasRelatedWork W2944010546 @default.
• W2108080169 hasRelatedWork W2978552006 @default.
• W2108080169 hasRelatedWork W3068005188 @default.
• W2108080169 hasRelatedWork W4233763500 @default.
• W2108080169 hasVolume "25" @default.
• W2108080169 isParatext "false" @default.
• W2108080169 isRetracted "false" @default.
• W2108080169 magId "2108080169" @default.
• W2108080169 workType "article" @default.